Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients with type 2 diabetes mellitus between 30 and 70 years of age.~2. Failure to triple OHA and on stable doses of insulin for atleast 3 months.~3. On vildagliptin,pioglitazone and metformin for atleast 3 months along with Insulin to maintain euglycemia.~4. HbA1c \< 8.5%.~5. Insulin requirement ≥0.4 IU/kg/d.~6. GAD antibody negative status.~Exclusion Criteria:~1. Patients with T1DM or secondary diabetes.~2. Patients with serum creatinine \> 1.5 mg/dl.~3. Abnormal liver function tests (defined as value of transaminases \> 3 times the upper value of normal or serum bilirubin higher than normal for the reference value for the laboratory).~4. History of cholecystitis/ cholelitiasis/ cholecystectomy~5. Seropositivity for HIV, HBsAg and HCV.~6. History of myocardial infarction or unstable angina in the previous 3 months.~7. History of malignancy~8. Patients with active infections.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group 1:Stem cell Recipient (Type: None): Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of \>0.4U/Kg for blood glucose control. They will undergo stem cell therapy initialy and G-CSF therapy at 2 months
- Group-2: Controls (Type: None): Type 2 Diabetes mellitus patients on full doses of vildagliptin+metformin+pioglitazone and on Insulin \>0.4U/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).